Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 3
2005 3
2006 5
2007 9
2008 6
2009 4
2010 6
2011 5
2012 10
2013 16
2014 14
2015 4
2016 8
2017 7
2018 6
2019 5
2020 4
2021 2
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25039915

101 results

Results by year

Filters applied: . Clear all
Page 1
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon A, Koh DM, Gill K, Uzzell M, Prior Y, Catovsky D. Chau I, et al. Br J Haematol. 2003 Mar;120(6):970-7. doi: 10.1046/j.1365-2141.2003.04226.x. Br J Haematol. 2003. PMID: 12648066 Free article. Clinical Trial.
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial.
Kühnl A, Peckitt C, Patel B, Ardeshna KM, Macheta MP, Radford J, Johnson R, Paneesha S, Barton S, Chau I, Begum R, Valeri N, Wotherspoon A, Du Y, Zerizer I, Cunningham D. Kühnl A, et al. Ann Hematol. 2020 Jan;99(1):105-112. doi: 10.1007/s00277-019-03842-4. Epub 2019 Nov 27. Ann Hematol. 2020. PMID: 31776726 Clinical Trial.
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T, Hara T, Shibata Y, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Goto N, Kito Y, Kasahara S, Yamada T, Sawada M, Miyazaki T, Takami T, Takeuchi T, Moriwaki H, Tsurumi H. Matsumoto T, et al. Hematol Oncol. 2017 Sep;35(3):288-295. doi: 10.1002/hon.2285. Epub 2016 Mar 21. Hematol Oncol. 2017. PMID: 26999778
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
Witzens-Harig M, Memmer ML, Dreyling M, Hess G. Witzens-Harig M, et al. BMC Cancer. 2013 Jun 25;13:308. doi: 10.1186/1471-2407-13-308. BMC Cancer. 2013. PMID: 23799873 Free PMC article. Clinical Trial.
101 results